Mizuho Trust & Banking Co. Ltd. held its stake in shares of Bio-Rad Laboratories Inc. (NYSE:BIO) during the third quarter, Holdings Channel reports. The institutional investor owned 8,100 shares of the company’s stock at the end of the third quarter. Mizuho Trust & Banking Co. Ltd.’s holdings in Bio-Rad Laboratories were worth $1,327,000 as of its most recent SEC filing.
Several other large investors also recently modified their holdings of the stock. Atlanta Capital Management Co. L L C boosted its stake in shares of Bio-Rad Laboratories by 2.5% in the second quarter. Atlanta Capital Management Co. L L C now owns 1,769,119 shares of the company’s stock valued at $253,019,000 after buying an additional 42,593 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Bio-Rad Laboratories by 4.4% in the second quarter. Vanguard Group Inc. now owns 1,498,194 shares of the company’s stock valued at $214,272,000 after buying an additional 63,322 shares during the last quarter. Acadian Asset Management LLC boosted its stake in shares of Bio-Rad Laboratories by 1.0% in the second quarter. Acadian Asset Management LLC now owns 943,069 shares of the company’s stock valued at $134,878,000 after buying an additional 8,923 shares during the last quarter. BlackRock Fund Advisors boosted its stake in shares of Bio-Rad Laboratories by 8.3% in the second quarter. BlackRock Fund Advisors now owns 808,020 shares of the company’s stock valued at $115,563,000 after buying an additional 62,178 shares during the last quarter. Finally, Levin Capital Strategies L.P. boosted its stake in shares of Bio-Rad Laboratories by 4.4% in the second quarter. Levin Capital Strategies L.P. now owns 796,062 shares of the company’s stock valued at $113,853,000 after buying an additional 33,600 shares during the last quarter. 63.23% of the stock is owned by institutional investors.
Shares of Bio-Rad Laboratories Inc. (NYSE:BIO) traded up 0.37% during midday trading on Friday, hitting $172.76. The company had a trading volume of 45,263 shares. The company has a market capitalization of $5.10 billion, a P/E ratio of 51.97 and a beta of 0.88. The firm’s 50 day moving average is $165.33 and its 200 day moving average is $153.50. Bio-Rad Laboratories Inc. has a 52 week low of $122.03 and a 52 week high of $174.02.
Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Tuesday, November 1st. The company reported $0.62 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.51 by $0.11. Bio-Rad Laboratories had a return on equity of 3.79% and a net margin of 4.75%. The company earned $508.75 million during the quarter, compared to analyst estimates of $480.60 million. During the same quarter last year, the company earned $0.59 earnings per share. The firm’s quarterly revenue was up 8.3% on a year-over-year basis. Equities research analysts anticipate that Bio-Rad Laboratories Inc. will post $2.77 EPS for the current year.
BIO has been the subject of several recent research reports. Jefferies Group increased their price target on Bio-Rad Laboratories from $200.00 to $225.00 and gave the company a “buy” rating in a research note on Wednesday, September 7th. CL King initiated coverage on Bio-Rad Laboratories in a research report on Wednesday, October 12th. They set a “buy” rating and a $180.00 target price on the stock. Finally, Zacks Investment Research upgraded Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 8th.
In other Bio-Rad Laboratories news, VP James R. Stark sold 1,299 shares of Bio-Rad Laboratories stock in a transaction dated Wednesday, November 9th. The stock was sold at an average price of $171.42, for a total transaction of $222,674.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 28.38% of the company’s stock.
Bio-Rad Laboratories Company Profile
Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of life science research and clinical diagnostics products. The Company manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.